Drug intelligence / Profile preview

IK15800

Development stage: Preclinical
Lead developer: InterK Peptide Therapeutics
Modality: Peptides
Administration: Subcutaneous, Intramuscular

Overview

IK15800 is a synthetic immunomodulating peptide developed by InterK Peptide Therapeutics as a vaccine adjuvant for cancer and viral pathogens, including Ebola. It acts synergistically with Toll-like receptor 9 (TLR9) agonists to induce type I interferons (IFNs), thereby enhancing vaccine efficacy. The peptide is characterized by its biostability in human serum and its ability to form a depot at the injection site, which facilitates prolonged immune stimulation. It is currently in preclinical development.

Other names: IK15800IK-15800IK 15800

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on IK15800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IK15800.

Explore the full profile